大摩:降威高(1066.HK)评级至与大市同步 目标价17港元
摩根士丹利发表报告指,威高股份(1066.HK)今年以来股价已上涨逾一倍,惟受疫情及中国地方政府集中採购影响,预期今年盈利增长将放缓,相信股价进一步上涨空间有限,因此将公司评级由增持,下调至与大市同步,但维持目标价17港元。
大摩指,新型肺炎疫情导致内地公立医院病人流量大降,今年1至5月份处方药销售按年下降23%。另外,而威高最近一次人造关节的中标价格亦下跌57%,故下调威高今年销售增长预测至4.3%,利润成长预期亦下调至3.6%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.